The Times – Our flu drug is not to be sniffed at, says Poolbeg Pharma chief Jeremy Skillington

The course of Jeremy Skillington’s year took a fateful turn in March when he took a call from Cathal Friel, chairman of Open Orphan, a clinical trials company listed on the Alternative Investment Market (AIM). At the time Skillington was tidying up the loose ends of the landmark €380 million sale of Irish biotech company […]